Screener
Xeris Biopharma Holdings, Inc. XERS Gain (loss) on extinguishment of debt
Gain (loss) on extinguishment of debt at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GainsLossesOnExtinguishmentOfDebt.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Income from operations | 5,173 | 4,482 | 13,089 | 1,392 |
| Other income (expense): | ||||
| Interest and other income | 1,455 | 948 | 2,657 | 2,123 |
| Loss on debt extinguishment, net | (30,782) | — | (30,782) | — |
| Interest expense | (6,947) | (7,358) | (13,831) | (14,663) |
| Total other expense | (36,274) | (6,410) | (41,956) | (12,540) |
| Net loss before income taxes | (31,101) | (1,928) | (28,867) | (11,148) |
| Income tax benefit | — | — | — | — |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Xeris Biopharma Holdings, Inc.'s gain (loss) on extinguishment of debt?
- Xeris Biopharma Holdings, Inc. (XERS) reported gain (loss) on extinguishment of debt of -$30.78M in Q2 2026.
- What does gain (loss) on extinguishment of debt mean?
- Gains or losses from retiring debt before maturity — gains when debt is repurchased below par, losses when premiums are paid for early redemption.
Ask your AI about Xeris Biopharma Holdings, Inc.'s gain (loss) on extinguishment of debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude